Category

• Pipeline2

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• AMD2
• Finance2
• Retina2
• Wet Amd2
• Clinical Trials1
• Finances1
• Injections1
• Research1
• Technology1

• Organizations: RevOpsis Therapeutics✕

Clear all

Pipeline

RevOpsis receives NEI grant for advancing retinal vascular disease candidate

The $1.8M funding will support clinical development of RO-104, a fully human modular tri-specific biologic targeting three angiogenic pathways for wet AMD.

Pipeline

RevOpsis raises $16.5M to advance nAMD tri-specific therapy

Seed funding will support IND-enabling clinical studies on the first monotherapy agent to target all three angiogenic pathways.